35 results about "Methyldopa" patented technology

A sympatholytic cardiovascular agent delivered by a drug delivery pump to a central nervous system site to alleviate symptoms of acute or chronic cardiac insult or impaired cardiac performance. The drug delivery pump can be external or implantable infusion pump (IIP) coupled with a drug infusion catheter extending to the site. A patient activator can command delivery of a dosage and/or an implantable heart monitor (IHM) coupled with a sensor can detect physiologic parameters associated with cardiac insult or impaired cardiac performance and trigger dosage delivery. The IIP and IHM can be combined into a single implantable medical device (IMD) or can constitute separate IMDs that communicate by any of known communication mechanisms. The sympatholytic cardiovascular agent is one of the group consisting of an alpha-adrenergic agonist and an alpha2-adrenergic agonist (e.g., clonidine, p-aminoclonidine, guanabenz, lidamidine, tizanidine, moxonidine, methyldopa, xylazine, guanfacine, detomidine, medetomidine, and dexmedetomidine).

Prostate cancer comes in various forms and has proven difficult to treat. Provided herein are various methods and compositions for treating all forms of prostate cancers with dopa decarboxylase (DDC) inhibitors. These dopa decarboxylase inhibitors include carbidopa (α-Methyl-dopahydrazine), MFMD (α-monofluoromethyldopa), NSD-1015 (3-hydroxybenzylhydrazine), Methyldopa (L-α-Methyl-3,4-dihydroxyphenylalanine) or benserazide, and the inhibitors may be used in combination. DDC inhibitors may also be used to inhibit the progression of prostate cancer to androgen-independence and neuroendocrine prostate cancer.

The invention relates to processing equipment and a processing method for methyldopa sewage. The equipment comprises a regulating tank, a Fenton oxidation reaction tank, a primary sedimentation tank, a hydrolysis acidification tank, an anoxia tank, an aerobic tank, and a secondary tank, wherein, the regulating tank, the Fenton oxidation reaction tank, the primary sedimentation tank, the hydrolysis acidification tank, the anoxia tank, the aerobic tank, and the secondary tank are connected in sequence and form integrated processing equipment. The processing equipment and the processing method for methyldopa sewage combine the advantages of advanced oxidation and biological processing together. Ammonia and nitrogen of methyldopa sewage processed by the processing equipment can be effectively degraded, and chroma and COD are decreased. Therefore the methyldopa sewage is processed to meet the demand of discharging into a pipe net. The processing equipment and the processing method for methyldopa sewage have the advantages of low processing cost, simple operation and easiness in control.

The invention discloses a recycling method and application of an L-methyldopa intermediate. The recycling method comprises the following steps: hydrolyzing L-3-(3,4-dimethoxy phenyl)-2-amino-2-methyl propionitrile hydrochloride by utilizing hydrochloric acid, and filtering to obtaining L-3-(3,4-dimethoxy phenyl)-2-methyl alanine hydrochloride and mother liquor, adding haloid salt or ammonium salt into the mother liquor, carrying out vacuum distillation, concentrating until volume is less than or equal to 1/3 of the original volume, and filtering, wherein a filter cake is namely the recycled 3-(3,4-dimethoxy phenyl)-2-methyl alanine hydrochloride solid. The recycling method disclosed by the invention has the advantages that L-methyldopa can be recycled from 3-(3,4-dimethoxy phenyl)-2-methyl alanine hydrochloride production waste liquor, and ammonia nitrogen and COD in wastewater can also be reduced, so that the recycling method accords with the green chemistry concept.

A tau aggregation inhibitor reduces tau aggregation in cells. The tau aggregation inhibitor can include a catechol structure-containing compound or a salt thereof, and the catechol structure-containing compound can be one of isoprenaline, dopamine, dobutamine, levodopa, levodopa/carbidopa, trimetoquinol, hexoprenaline, methyldopa, and droxidopa. One example of the catechol structure-containing compound is isoprenaline, which can be d-enantiomer of isoprenaline or d/l-racemic mixture of isoprenaline. Tauopathies to be prevented or treated by the inhibitor include AD, Down's syndrome, Pick's disease, corticobasal degeneration, and progressive supranuclear palsy.

The invention discloses a method for refining carbidopa, which comprises the following steps: diluting a crude carbidopa product with water, regulating the pH value to below 6.5 with acid, and heating to 50-110 DEG C under the nitrogen protection or/and reducer addition condition, thereby obtaining a crude product system; adding a decolorant into the crude product system to decolorize at 50-110 DEG C for 5-60 minutes; after decolorizing, filtering while the crude product system is hot to obtain a filtrate, stirring and cooling the filtrate to 0-30 DEG C, and continuing stirring at 0-30 DEG C for 0.5-5 hours to obtain a refined system; and filtering the refined system, washing the filter cake with water, and carrying out vacuum drying to obtain the finished carbidopa product. The method disclosed by the invention has the advantages of simple preparation method, favorable controllability, strong operability, high methyldopa (impurity) removal rate, high yield and low production cost, can easily implement industrial production, has high economic benefit in the industrial production, can be easily popularized, and has wide application prospects.

The invention relates to a manufacturing method for an electrochemical transducer, and particularly relates to the manufacturing method for a novel carbon nano tube-based electrode. Compared with non-modified electrodes, the modified electrode of the transducer prepared by the method has obviously enhanced volt-ampere response of MD (methyldopa) on the surface and is successfully used for simultaneously detecting the MD and HCT (hydrodiuril) for the first time, and the oxidation potential of the MD is below 220mV. The transducer has high stability, high sensitivity, long-term use stability, and remarkable volt-ampere repeatability. The detection result to practical samples shows that the prepared transducer has very good practicability.

The invention relates to a preparation process of L-methyldopa methyl ester and belongs to the field of organic chemical synthesis. The preparation process of the L-methyldopa methyl ester comprises the following steps of 1, sequentially adding L-methyldopa and methanol and introducing hydrogen chloride; 2, at 0-45 DEG C, performing esterification reaction for 10-72 H; 3, after esterification reaction is completed, performing filtering, dissolution, neutralization, crystallization, centrifugation and drying to obtain a finished product. The preparation process of the L-methyldopa methyl estercan provide increased yield and reduced energy consumption, and meanwhile, through circulated application of a mother solution, the cost can be reduced and good environment friendliness can be provided.

The invention relates to a method for preparing methyldopa or L-methyldopa through microwave basic hydrolysis 5-methyl-5-(3,4-dimethoxy benzyl) hydantoin. Various alkaline aqueous solutions with different concentrations are adopted to hydrolyze 5-methyl-5-(3,4-dimethoxy benzyl) hydantoin under different microwave power and radiation times to prepare DL-alpha-methyl-(3,4-dimethoxy benzyl)-alpha-aminopropionic acid salt which is hydrolyzed in an acid aqueous solution to prepare methyldopa[DL-alpha-methyl-(3,4-dimethoxy benzyl)-alpha-aminopropionic acid] or L-methyldopa[L-alpha-methyl-(3,4-dimethoxy benzyl)-alpha-aminopropionic acid]. When the method is used for hydrolyzing DL-alpha-methyl-(3,4-dimethoxy benzyl)-alpha-aminopropionic acid (or L-alpha-methyl-(3,4-dimethoxy benzyl)-alpha-aminopropionic acid), the molar ratio of a substrate and hydrogen bromide (Hbr) is 1:10-20, and the molar ratio of the substrate and chlorine hydride (HCl) is 1:10-30. The hydrolysis reaction is smooth when acid using amount is big, and disacidify pressure after the hydrolysis reaction is reduced when the acid using amount is small.

The present disclosure relates to methods of reducing the number of abnormal PBMC cells in a leukemia patient. The methods may include administering an effective amount of a drug, which may not be indicated for leukemia, or an antibody-drug conjugate. The antibody-drug conjugate includes an antibody selected from the group consisting of an anti-α₂-adrenoreceptor antibody, an anti-β adrenoceptor antibody, an anti-trace amine-associated receptor 1 antibody, an anti-dopamine receptor antibody, and an anti-serotonin receptor antibody; a drug selected from the group consisting of isoproterenol, methyldopa, olanzapine, and a derivative thereof; and a linker that conjugates the antibody and the drug.

Disclosed is a medicament for treating cardiovascular and cerebrovascular diseases which comprises the components of (by weight ratio) sodium ascorbate 2-3, chlorhydric pyridoxine 0.1-0.15, thiamine 0.1-0.15, methyldopa 0.05-0.1, Urapidil 0.05-0.1, puerarin 0.1-0.15, xinkeshu tablet 0.05-0.1, xuekang capsule 0.05-0.1, ginkgo leaf tablet 0.1-0.15, fresh vegetable and fruit maceration extract 20-40, and distilled water 77.3-56.